Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
    31.
    发明授权
    Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof 有权
    聚合物共轭的MetAP2抑制剂及其使用的治疗方法

    公开(公告)号:US09320805B2

    公开(公告)日:2016-04-26

    申请号:US13696743

    申请日:2011-05-25

    申请人: John S. Petersen

    发明人: John S. Petersen

    摘要: One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.

    摘要翻译: 本发明的一个方面提供了聚合物缀合的MetAP2抑制剂。 虽然不受任何特定理论的约束,但是认为通过本文所述的接头偶联MetAP2抑制性核提供对母体小分子具有优异功效的化合物和优异的药物动力学特征。 在本发明的一个方面,缀合有共轭的MetAP2抑制剂可用于治疗疾病的方法,包括向有需要的受试者施用治疗有效量的聚合物缀合的MetAP2抑制剂。

    Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof
    32.
    发明申请
    Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof 有权
    聚合物共轭MetAP2抑制剂及其使用的治疗方法

    公开(公告)号:US20130216494A1

    公开(公告)日:2013-08-22

    申请号:US13696743

    申请日:2011-05-25

    申请人: John S. Petersen

    发明人: John S. Petersen

    IPC分类号: A61K47/48 A61K31/336

    摘要: One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.

    摘要翻译: 本发明的一个方面提供了聚合物缀合的MetAP2抑制剂。 虽然不受任何特定理论的约束,但是认为通过本文所述的接头偶联MetAP2抑制性核提供对母体小分子具有优异功效的化合物和优异的药代动力学特征。 在本发明的一个方面,缀合有共轭的MetAP2抑制剂可用于治疗疾病的方法,包括向有需要的受试者施用治疗有效量的聚合物缀合的MetAP2抑制剂。

    Direct compression polymer tablet core
    36.
    发明申请
    Direct compression polymer tablet core 有权
    直接压缩聚合物片芯

    公开(公告)号:US20090291135A1

    公开(公告)日:2009-11-26

    申请号:US12461143

    申请日:2009-08-03

    IPC分类号: A61K9/20 A61K47/32

    摘要: The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.

    摘要翻译: 本发明提供一种片芯,其包含至少约95重量%的脂族胺聚合物。 本发明还提供一种生产包含至少约95重量%的脂族胺聚合物树脂的片芯的方法。该方法包括压缩脂族胺聚合物以形成片芯的步骤。 片芯可进一步包括一种或多种赋形剂。 在该实施方案中,制备片芯的方法包括以下步骤:(1)将脂族胺聚合物水合至期望的水分含量; (2)将脂族胺聚合物与赋形剂混合,使得聚合物包含至少约95重量%的所得共混物; 和(3)压缩混合物以形成片芯。 本发明还涉及一种包含脂族胺聚合物核心的包衣片剂,其中该涂料是水基涂料。

    Poly(diallylamine)-based bile acid sequestrants
    40.
    发明授权
    Poly(diallylamine)-based bile acid sequestrants 有权
    聚(二烯丙基胺)为基础的胆汁酸多价螯合剂

    公开(公告)号:US07125547B2

    公开(公告)日:2006-10-24

    申请号:US10647665

    申请日:2003-08-25

    IPC分类号: A61K31/787 A61P3/06

    摘要: The present invention relates to a method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a poly(diallylamine) polymer which is substituted with hydrophobic groups. The hydrophobic groups can be a substituted or unsubstituted, straight chain or branched C3–C24-alkyl group, an aralkyl group or an aryl group.

    摘要翻译: 本发明涉及一种从患者中除去胆汁酸的方法和本方法中使用的某些聚合物。 该方法包括向患者施用治疗有效量的聚合物组合物的步骤,该聚合物组合物包括被疏水基团取代的聚(二烯丙基胺)聚合物。 疏水基团可以是取代或未取代的直链或支链C 3 -C 24 - 烷基,芳烷基或芳基。